



## FAM65B controls the proliferation of transformed and primary T cells


### Supplementary Materials




**Supplementary Figure S1: Re-expression of FAM65B does not modify FOXO1 expression in Jurkat cell line and FAM65B is phosphorylated in Jurkat cell line.** (A) Expression of FOXO1 analysis in lysates from peripheral blood T cells (PBT), used as positive control and Jurkat cells transfected with GFP or FAM65B GFP. (B) Lysates from Jurkat cells transfected with GFP or FAM65B GFP were treated with  $\lambda$  phosphatase and analyzed by immunoblotting with the indicated antibodies.




**Supplementary Figure S2: Inhibition of HDAC6 inhibits T cell proliferation and blocks cell cycle progression in G2/M.** (A) Jurkat cells were treated with increasing dose of HDAC6 inhibitor for 18 hours and their cell cycle was analyzed by flow cytometry. Results are representative of three experiments. Graphs represent the proliferation of cells (left panels) and the proportion of cells in G2/M phase (right panel) in function of the treatment. (B) Human primary T cells were stained with CTV and stimulated in vitro with anti-CD3 and anti-CD28 coated beads in presence of increasing dose of HDAC6 inhibitor. The effect of this inhibitor on cell proliferation and cell mortality was measured by flow cytometry after three days. Results are representative of three experiments. Means of the percentage of proliferating cells were plotted (right panel).



**Supplementary Figure S3: Etoposide blocks cell cycle progression in G2/M.** Jurkat cells were treated with increasing dose of etoposide for 18 hours and their cell cycle was analyzed by flow cytometry. Results are representative of three experiments. Graphs represent the proportion of cells in G2/M phase (right panel) in function of the treatment.



**Supplementary Figure S4: CD45 RA positive cells are less prone to proliferate.** Human primary CD45 RA+ and RO+ T cells were stained with CTV and stimulated in vitro with anti-CD3 and anti-CD28 coated beads. Cell proliferation was measured by flow cytometry after three days. Results are representative of three experiments. Means of the percentage of proliferating cells were plotted (lower panel).



**Supplementary Figure S5: Analyze of the expression of FAM65B after transfection of siRNA CT or FAM65B.** Four days after transfection with siRNA CT or FAM65B, the human primary T cells were stained with anti-FAM65B antibodies or control immunoglobulin. These control experiments were systematically performed to check for extinction of FAM65B expression.

**Supplementary Table S1: sequences of the primers use**

<b>Séquence (5' -&gt; 3')</b>		
peGFP-FAM65B RL151-152AA	F R	tgtatccagcgaGCcGCccaggatggtgccagcaaatgaagca tgcttcattttgctggcaccatctggGCgGCTcgctggataca
peGFP-FAM65B S(x5)A	S21A_F S21A_R S37A_F S37A_R S523A_F S523A_R S535A_F S535A_R S341A_F S341A_R	atcattagaagccagGcctttgcegggttcagcggc gccgctgaaacccgcaaaggCctggttctaataatgat ggcgatccagggtaacGccttcattgaaaatt aattttcaatgaaggCgttacacctggatcgcc ctggtcaagaggctcacaGCTgcagaggtgccaatggcc ggccattggcacctctgcAGCtgtgagcctcttgaccag atggccacagacaggctgctcGCTgagggttctgttggtgga tccaccaacagaaccctcAGCgagcagcctgtctgtggccat cccttcagaggagaatgGCCatgtacagccagggtacc ggtaccctggctgtacatGGCattctcctctgaaggg
pmCherry-FAM65B	F R	atacatACCGGTCGCCACATGgtgagcaagggcgaggagga atgtatGCGGCCCGCtactgtacagctcgtccatgccg
pEF-FAM65B-myc	F R	atacatACTAGTatgttgtaggatcccagctcttttcgcc gtcatgaattggatgatattctaaaaaagGATATCatacat
ppia (qRT-PCR)	F R	ggtgacttcacacgataatg acaagatgcaggaccctgat
Fam65b (qRT-PCR)	F R	gcgaggttaacctcagcag ccttcaggtgtgactttggc